Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?;Existe-t-il des arguments pour instituer un traitement à visée étiologique dès la première poussée de sclérose en plaques?

Presse Medicale

Volumn 33, Issue 3, 2004, Pages 180-186

  Vermersch, Patrick ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; METHYLPREDNISOLONE;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; TREATMENT INDICATION;

EID: 1242336943     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98519-3     Document Type: Review

References (30)

1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: A geographical based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
2. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-56.
3. Achiron A, Barak Y. Multiple sclerosis - From probable to definite diagnosis. A 7-year prospective study. Arch Neurol 2000; 57: 974-9.
4. Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 2000; 55: 689-93.
5. Poser CM, Paty D, Scheinberg L, et al. New diagnosis criteria for multiple sclerosis. Ann Neurol 1983; 13: 227-31.
6. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon b-1a therapy initiated during the first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
7. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
8. Beck RW, Chandler DL, Cole SR, et al. Interferon β-1a for early multiple sclerosis: Champs trial subgroup analyses. Ann Neurol 2002; 51: 481-90.
9. Paty DW, Li DK, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180-5.
10. Barkhof F, Filippi M, Miller DH et al. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis. J Neurol 1997; 244: 36-84.
11. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
12. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI. Brain magnetic resonance imaging in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol 1993; 50: 841-6.
13. O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998; 121: 495-503.
14. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64.
15. Sailer M, O'Riordan JI, Thompson AJ et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52: 599-606.
16. Brex PA, Miszkiel KA, O'Riordan JI et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow-up MRI. J Neurol Neurosurg Psychiatry 2001; 70: 390-1.
17. Koudriavtseva T, Thompson AJ, Fiorelli M et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62: 285-7.
18. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999; 53: 139-42.
19. Simon JH, Jacobs LD, Kinkel RP. Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 2001; 57: 1888-90.
20. Werring DJ, Brassat D, Droogan AG et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis. A serial diffusion MRI study. Brain 2000; 123: 1667-76.
21. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
22. Bhakoo KK, Pearce D. In vitro expression of N-acetyl-aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000; 74: 254-62.
23. Fu L, Matthews PM, De Stefano N. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 1469-77.
24. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
25. Ferguson B, Matyszak MK, Esiri MM, Perry VH, Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
26. Kornek B, Storch M, Weissert R et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am J Pathol 2000; 168: 267-76.
27. Bitsch A, Schuchardt J, Bunkowski S et al. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000; 123: 1174-3.
28. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute multiple sclerosis. Neurology 2001; 57: 1248-52.
29. George EB, Glass JD, Griffin JW. Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J Neurosci 1995; 15: 6445-52.
30. Fern R, Ransom BR, Waxman SG. Autoprotective mechanisms in the CNS: some new lessons from white matter. Mol Chem Neuropathol 1996; 27: 107-29.